NASHUA, N.H.

纳舒厄，新罕布什尔州

,

，

March 23, 2026

2026年3月23日

/PRNewswire/ -- Resonetics

/PRNewswire/ -- Resonetics

®

®

announced today the successful completion of its acquisition of Resolution Medical, which further strengthens its ability to deliver integrated, end-to-end device solutions for customers in the interventional, structural heart, and neuromodulation markets.

今天宣布成功完成了对Resolution Medical的收购，此举进一步增强了其为介入、结构性心脏病和神经调节市场客户提供集成的端到端设备解决方案的能力。

The acquisition expands Resonetics' design, finished device and sub-assembly capabilities, enabling broader support across the full product lifecycle from early concept and development through commercialization and scaled production. By incorporating Resolution Medical's biosimulation, design, new product introduction (NPI), and cleanroom assembly expertise with Resonetics' AGILE Product Development.

此次收购扩展了Resonetics的设计、成品设备和子组件能力，能够更广泛地支持整个产品生命周期，从早期概念和开发到商业化和规模化生产。通过将Resolution Medical的生物仿真、设计、新产品导入（NPI）和洁净室装配专业知识与Resonetics的AGILE产品开发相结合。

®

®

group, precision component manufacturing, advanced materials, and battery technologies, Resonetics creates a more seamless platform that helps OEMs reduce complexity, improve execution, and bring innovative devices to market faster.

集团、精密组件制造、先进材料和电池技术，Resonetics 创建了一个更加无缝的平台，帮助原始设备制造商降低复杂性、提高执行效率，并更快地将创新设备推向市场。

'This marks an important milestone in Resonetics' growth strategy,' said Kevin Kelly, CEO of Resonetics. 'As device complexity increases, our customers are looking for partners who can take greater ownership across development and manufacturing. Bringing Resolution Medical into the Resonetics platform strengthens our ability to execute integrated programs at scale and support the next generation of innovative therapies.'.

“这标志着Resonetics增长战略中的一个重要里程碑，” Resonetics首席执行官凯文·凯利表示。“随着设备复杂性的增加，我们的客户正在寻找能够在开发和制造过程中承担更多责任的合作伙伴。将Resolution Medical引入Resonetics平台增强了我们大规模执行综合项目的能力，并支持下一代创新疗法。”

The combination further strengthens Resonetics' ability to support customers in high-growth areas such as neuromodulation, where close coordination across device design, electronics, batteries, and assembly is essential. With expanded integration and collaboration, customers benefit from more efficient program execution and greater confidence as devices progress toward commercialization..

该组合进一步增强了Resonetics在神经调节等高增长领域支持客户的能力，在这些领域，设备设计、电子元件、电池和组装之间的紧密协调至关重要。通过加强整合与合作，客户能够受益于更高效的项目执行以及在设备迈向商业化过程中更大的信心。

'Joining Resonetics allows us to amplify what we do best,' said Peter Herman, CEO of Resolution Medical. 'Our team has built a strong reputation for solving complex engineering challenges. Now, as part of Resonetics, we can extend that impact by leveraging broader manufacturing depth, integrated component content, global resources, and expanded technical capabilities while continuing to deliver the responsiveness and expertise our customers expect.'.

“加入Resonetics使我们能够将最擅长的事情做得更好，”Resolution Medical首席执行官彼得·赫尔曼表示。“我们的团队在解决复杂工程挑战方面建立了良好的声誉。现在，作为Resonetics的一部分，我们可以通过利用更广泛的制造深度、集成的组件内容、全球资源和扩展的技术能力来扩大影响力，同时继续提供客户期望的响应速度和专业性。”

The acquisition builds on Resonetics' recent investments in battery, lead, and implantable and external pulse generator (IPG / EPG) manufacturing, expanding in and supporting more comprehensive device solutions. Together, the combined organization positions Resonetics as a strategic partner to serve customers innovating complex, regulated medical devices that demand both technical depth and manufacturing scale..

此次收购建立在Resonetics近期对电池、导线以及植入式和外部脉冲发生器（IPG/EPG）制造的投资基础之上，进一步扩展并支持更全面的设备解决方案。合并后的组织使Resonetics成为战略合作伙伴，为创新复杂且受监管的医疗设备客户提供服务，满足其对技术深度和制造规模的需求。

About Resonetics

关于Resonetics

Founded in 1987, Resonetics is a pioneer in advanced engineering and manufacturing solutions for the medical device industry. Resonetics is a leader in laser processing, nitinol manufacturing, thin-wall stainless steel, nitinol & precious metal tubing, and photochemical machining. With strategically located LightSpeed Labs.

成立于1987年，Resonetics 是医疗设备行业先进工程和制造解决方案的先驱。Resonetics 是激光加工、镍钛诺制造、薄壁不锈钢、镍钛诺及贵金属管材和光化学蚀刻的领导者。其战略性布局的 LightSpeed 实验室。

®

®

and AGILE Product Development

敏捷产品开发

®

®

centers, Resonetics is committed to quality, speed, innovation, and a great customer experience. The company is ISO 13485:2016 certified with 18 facilities and more than 3,000 associates in the United States, Canada, Costa Rica, Israel, and Switzerland. Resonetics is backed by leading private equity firms Carlyle and GTCR.

中心，Resonetics致力于质量、速度、创新和卓越的客户体验。公司通过了ISO 13485:2016认证，在美国、加拿大、哥斯达黎加、以色列和瑞士拥有18个设施和超过3,000名员工。Resonetics由领先的私募股权公司凯雷集团（Carlyle）和GTCR支持。

Learn more at .

了解更多，请访问。

www.resonetics.com

www.resonetics.com

.

。

About GTCR

关于GTCR

Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors.

成立于1980年的GTCR是一家领先的私募股权公司，专注于《领导者战略™》——在核心领域寻找并与管理领导者合作，通过自然增长和战略性收购来识别、获取并打造市场领先的公司。GTCR专注于投资商业与消费者服务、金融服务与技术、医疗保健以及技术、媒体和电信行业的企业的转型增长。

Since its inception, GTCR has invested more than $30 billion in approximately 300 companies, and the firm currently manages approximately $50 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit .

自成立以来，GTCR已向约300家公司投资超过300亿美元，目前该机构管理着近500亿美元的股权资本。GTCR总部位于芝加哥，在纽约和西棕榈滩设有办事处。欲了解更多信息，请访问。

www.gtcr.com

www.gtcr.com

. Follow us on

. 关注我们

LinkedIn

领英

.

。

About Carlyle

关于卡莱尔

Carlyle (NASDAQ:

卡尔莱尔 (纳斯达克:

CG

计算机图形学

) is a global investment firm with deep industry expertise that deploys private capital across its business and operates through three segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $477 billion of assets under management as of December 31, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest.

）是一家具有深厚行业专业知识的全球投资公司，跨其业务部署私人资本，并通过三个部门运营：全球私募股权、全球信贷和凯雷阿尔卑斯投资。截至2025年12月31日，凯雷管理的资产达4770亿美元，其宗旨是明智投资，为其投资者、投资组合公司以及我们生活和投资的社区创造价值。

Carlyle employs more than 2,500 people in 27 offices across four continents. Further information is available at .

卡莱尔在四大洲的27个办事处雇用了2500多名员工。更多信息可查阅。

carlyle.com

卡莱尔集团

. Follow Carlyle on LinkedIn at The Carlyle Group and on X at @OneCarlyle.

在LinkedIn上关注凯雷集团The Carlyle Group，或在X平台@OneCarlyle关注凯雷。

SOURCE Resonetics, LLC

源共振技术有限责任公司

21

21

%

%

more press release views with

更多新闻稿浏览量与

Request a Demo

请求演示